According to the DrugBank database, multiple drugs targeting IL-13 and IL-33, or carried by FABP3 to the heart, have been developed and either approved or are under investigation for conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease and bacterial growth. This evidence concerns the gene IL33 and asthma.